Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arecor Therapeutics PLC ( (GB:AREC) ) has issued an update.
Arecor Therapeutics has received its first $0.5 million commercial milestone payment from Ligand Pharmaceuticals under a royalty financing agreement tied to royalties and milestones from AT220 and AT292. The payment follows a prior $7 million upfront and forms part of up to $4 million in potential milestones, with a further $0.5 million expected in the second half of 2026 and $3 million contingent on future commercial achievements.
The company said the non-dilutive funds from the Ligand agreement are helping to accelerate development of its lead insulin candidate AT278, including preparation for a Phase 2 clinical trial in combination with Sequel Med Tech’s twiist automated insulin delivery system planned to start in the second half of 2026. The milestone reinforces Arecor’s funding position and supports its strategy to advance differentiated insulin therapies in the competitive diabetes treatment landscape.
The most recent analyst rating on (GB:AREC) stock is a Hold with a £84.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.
Spark’s Take on AREC Stock
According to Spark, TipRanks’ AI Analyst, AREC is a Neutral.
Arecor Therapeutics’ score is driven by positive corporate events, including strategic partnerships and IP expansion, which bolster its market position. However, financial performance challenges, such as ongoing losses and cash flow issues, weigh heavily on the overall score. Technical analysis and valuation present a neutral outlook, reflecting the typical risks and opportunities in the biotech sector.
To see Spark’s full report on AREC stock, click here.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a Cambridge, UK-based clinical-stage biotech company focused on developing advanced therapeutics to reduce treatment burden and improve outcomes for people with diabetes, obesity and other cardiometabolic diseases. Its lead product, AT278, is an ultra-concentrated, ultra-rapid-acting insulin being co-developed with Sequel Med Tech’s twiist automated insulin delivery system to target a large and growing diabetes market.
Average Trading Volume: 17,458
Technical Sentiment Signal: Sell
Current Market Cap: £25.11M
Find detailed analytics on AREC stock on TipRanks’ Stock Analysis page.